LIVTENCITY Drug Patent Profile

Which patents cover Livtencity, and what generic alternatives are available?

Livtencity is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-two patent family members in twenty-three countries.

The generic ingredient in LIVTENCITY is maribavir. One supplier is listed for this compound. Additional details are available on the maribavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Livtencity

Livtencity was eligible for patent challenges on November 23, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 23, 2028. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LIVTENCITY

International Patents:	42
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	842
Drug Prices:	Drug price information for LIVTENCITY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIVTENCITY
What excipients (inactive ingredients) are in LIVTENCITY?	LIVTENCITY excipients list
DailyMed Link:	LIVTENCITY at DailyMed

See drug prices for LIVTENCITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LIVTENCITY

Constraining patent/regulatory exclusivity:

FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET

NDA:

215596

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LIVTENCITY

Drug Class	Cytomegalovirus pUL97 Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Cytomegalovirus pUL97 Kinase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for LIVTENCITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVTENCITY	Tablets	maribavir	200 mg	215596	3	2025-11-24

US Patents and Regulatory Information for LIVTENCITY

LIVTENCITY is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes			Y	Y
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for LIVTENCITY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Livtencity	maribavir	EMEA/H/C/005787LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents.	Authorised	no	no	yes	2022-11-09

International Patents for LIVTENCITY

See the table below for patents covering LIVTENCITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2022395001
Australia	2025202348
Canada	3237758

Last updated: July 30, 2026

LIVTENCITY (maribavir) market dynamics and financial trajectory: launches, uptake, pricing, and loss of exclusivity risk

LIVTENCITY (maribavir) has built a niche revenue base in post–transplant and refractory cytomegalovirus (CMV) settings, with sales tied to the size of the eligible population, payer coverage, and competitive pressure from valganciclovir/ganciclovir and newer CMV programs. Near-term commercial trajectory is driven by substitution for older off-label or resistant populations and by continued label expansion into pragmatic use cases; long-term revenue exposure is shaped by patent and regulatory exclusivity cliffs and by generics/biosimilar-like competitive entry risk for CMV antivirals.

What is LIVTENCITY (maribavir) and what approved uses drive demand?

LIVTENCITY is an oral antiviral (maribavir) for treatment of post-transplant CMV infection in adults who are refractory to, or intolerant of, other therapies. Demand is concentrated in transplant centers managing resistant or difficult-to-treat CMV disease, where clinicians seek an alternative mechanism and improved tolerability relative to older agents.

Which clinical setting is the commercial engine?

• Post-transplant CMV infection requiring therapy after failure or intolerance to standard antivirals (historically ganciclovir/valganciclovir-based regimens and other approaches used by practice).
• Patient identification depends on:
  • documented refractory/intolerant status
  • ongoing viral monitoring workflows
  • transplant center treatment protocols and formulary placement

How does maribavir differ in practice from older CMV antivirals?

• Maribavir targets a different CMV process than nucleoside analogs used in valganciclovir/ganciclovir regimens.
• Clinical adoption tends to correlate with resistance/refractory status and intolerance tolerance, which limits TAM versus first-line CMV treatment.

How have LIVTENCITY sales performed and what is the financial trajectory?

A defensible “financial trajectory” requires sales data for specific reporting periods, revenue growth rates, gross margin, and geographic breakdown. No sourceable, complete financial dataset for LIVTENCITY was provided here, and producing a quarter-by-quarter or year-by-year sales narrative without cited figures would violate an accuracy requirement.

What market dynamics affect LIVTENCITY uptake: reimbursement, formularies, and transplant center behavior?

LIVTENCITY is exposed to payer and institutional decision-making typical for high-cost specialty antivirals.

Payer coverage dynamics

• Coverage tends to hinge on documentation of:
  • refractory or intolerant status
  • failure of prior standard therapy
  • line-of-therapy criteria and durational thresholds
• If payers tighten prior authorization or require specific laboratory endpoints, real-world use can slow even if clinical uptake remains steady.

Provider workflow dynamics

• CMV care is protocolized within transplant programs.
• Uptake rises when:
  • transplant pharmacists and infectious disease teams recognize maribavir as a standard-of-care option for refractory/intolerant cases
  • viral load monitoring and response metrics align with prescribing patterns

Hospital inventory and specialty pharmacy distribution

• Like other specialty antivirals, channel structure affects turnaround time and adherence.
• Commercial execution often concentrates through:
  • specialty distribution networks
  • bridge-to-infusion or oral regimen sequencing
  • transplant center-specific purchasing rules

What is the pricing and reimbursement structure for LIVTENCITY?

Pricing and net price are determined by WAC, rebates, and negotiated payer contracts. A complete valuation-grade pricing analysis requires WAC and net revenue data. No pricing dataset with citations was supplied here, so no numeric pricing trajectory can be reported.

What competitor landscape pressures LIVTENCITY: valganciclovir alternatives and other CMV programs?

LIVTENCITY’s main commercial pressure comes from:

• continuation or optimization of nucleoside analog therapy strategies
• switching approaches within transplant center CMV algorithms
• competing CMV drug pipelines and label expansions by other antiviral classes

How does competitive substitution happen in CMV care?

• In refractory/intolerant populations, substitution depends on:
  • perceived risk of toxicity and tolerability
  • resistance testing availability
  • time-to-response expectations
• If older agents gain “effective salvage” positioning through protocol refinements or payer-favorable coverage, maribavir share can compress.

What clinical outcomes drive payer and physician willingness to switch?

• Shorter time to viral load reduction supports clinical and economic rationale.
• Safety and tolerability can influence continuation and dose management, indirectly affecting treatment duration and downstream prescribing.

How does LIVTENCITY compare with other CMV antivirals on commercial risk: switching vs resistance niches?

Maribavir is commercially less exposed to broad first-line CMV prescribing volume than agents intended for prophylaxis or initial treatment. That niche focus lowers volume ceiling but can stabilize revenue if:

• refractory/intolerant case incidence is stable
• payer policies remain aligned with label-defined access
• transplant centers keep a consistent switching algorithm

Key comparison axes:

• breadth of indication and line-of-therapy definition
• probability of being chosen after failure vs chosen up front
• persistence driven by tolerability and clinical response durability
• access constraints via prior authorization

When does LIVTENCITY lose exclusivity and what generic entry risks exist?

Exclusivity timelines require specific U.S. patent and regulatory exclusivity data (Orange Book, listed patents, expiration dates, and relevant pediatric exclusivities). No Orange Book or patent listing dataset was provided here, so no expiration dates or loss-of-exclusivity calendar can be stated.

What is the Orange Book status of LIVTENCITY and which patents control formulation and method-of-use?

A complete Orange Book status summary includes:

• all listed U.S. patents
• patent types (composition, formulation, method-of-use, etc.)
• expiration dates
• pediatric exclusivity or other exclusivity extensions
• any ongoing Paragraph IV certifications

No Orange Book listing information with citations is available in the provided context, so this cannot be accurately produced.

Has LIVTENCITY faced Paragraph IV challenges or patent litigation?

Paragraph IV challenge status depends on FDA Orange Book AND litigation dockets (Hatch-Waxman suits, settlements, and court rulings). No cited litigation record was provided here, so no settlement or generic entry scenario can be reported.

What regulatory milestones and FDA pathway factors affect LIVTENCITY growth?

A reliable regulatory trajectory requires:

• approval dates
• label expansion timeline
• changes in post-marketing requirements
• safety updates that affect prescribing

No FDA milestone dataset was supplied here, so no event-by-event regulatory timeline can be created.

How does geographic coverage influence LIVTENCITY revenue exposure?

LIVTENCITY’s market is primarily driven by U.S. transplant center adoption, with ex-U.S. sales dependent on local reimbursement rules, tendering practices, and health technology assessment outcomes.

A geographic breakdown needs region-level net sales or at least territory reporting from company disclosures. None was provided, so territory-specific commercial dynamics cannot be quantified.

What manufacturing and supply risks could constrain LIVTENCITY revenue?

Supply constraints for specialty oral antivirals can include:

• active ingredient availability
• finished dose manufacturing capacity
• distribution lead times

A manufacturing risk map needs inspection history, supply continuity communications, and CMC disclosures. No such dataset is available here.

How strong is the patent estate for LIVTENCITY from an investment and licensing perspective?

Patent estate strength analysis requires:

• listed patent counts and remaining term
• claim scope on composition, polymorph/formulation, and method-of-use
• freedom-to-operate risk and known design-around possibilities

No patent data was provided, so no patent strength assessment can be generated.

---

Key Takeaways

• LIVTENCITY demand is concentrated in post-transplant CMV infection patients who are refractory to or intolerant of standard therapies, which limits TAM but supports revenue stability when access and switching protocols remain favorable.
• Market dynamics are dominated by payer authorization criteria, transplant center workflow adoption, and competitive substitution within CMV salvage algorithms.
• A complete financial trajectory and exclusivity risk calendar require Orange Book and company sales disclosures, but none are present in the provided input, so no numeric projection or specific patent-loss date can be stated here.

FAQs

1. What patient criteria for refractory or intolerant CMV infection most affect LIVTENCITY prescription volume?
2. How do prior authorization requirements change real-world access to maribavir in transplant centers?
3. Which competing CMV antivirals most commonly substitute for maribavir after treatment failure?
4. What does the LIVTENCITY reimbursement pathway look like across commercial vs Medicare plans?
5. How do patent and exclusivity expirations typically affect generic entry timing for specialty antivirals like maribavir?

References

No sources were provided in the prompt to cite for sales, pricing, Orange Book status, exclusivity dates, or litigation records.

DrugChatter Q&A for LIVTENCITY

Livtencity approval date fda?
Livtencity fda approval date?
Livtencity approval letter march 23?
Livtencity approval letter november 23 2021?
Livtencity maribavir fda approval letter regulatory project manager?